



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

PEER-REVIEW REPORT

Name of journal: Artificial Intelligence in Cancer

Manuscript NO: 66932

Title: Therapeutic tumor vaccines - a rising star to benefit cancer patients

Reviewer's code: 00502951

Position: Peer Reviewer

Academic degree: PhD

Professional title: Professor

Reviewer's Country/Territory: Canada

Author's Country/Territory: China

Manuscript submission date: 2021-04-10

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-04-14 20:44

Reviewer performed review: 2021-04-21 19:32

Review time: 6 Days and 22 Hours

Scientific quality	<input checked="" type="checkbox"/> Grade A: Excellent [] Grade B: Very good [] Grade C: Good [] Grade D: Fair [] Grade E: Do not publish
Language quality	<input checked="" type="checkbox"/> Grade A: Priority publishing [] Grade B: Minor language polishing [] Grade C: A great deal of language polishing [] Grade D: Rejection
Conclusion	[] Accept (High priority) [] Accept (General priority) <input checked="" type="checkbox"/> Minor revision [] Major revision [] Rejection
Re-review	<input checked="" type="checkbox"/> Yes [] No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous [] Onymous Conflicts-of-Interest: [] Yes <input checked="" type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

SPECIFIC COMMENTS TO AUTHORS

General comments: This is a well-written and thoughtfully organized overview of the current status of the development of therapeutic tumor vaccines. The main types, tumor cell vaccines, dendritic cell vaccines, polypeptide vaccines, viral/bacterial vector vaccines, and nucleic acid vaccines are accurately described. Their advantageous features as well as impediments are discussed and the results emerging from recent and current clinical trials highlighted. Specific comments: 1. It would be good to comment on how could the current massive use of mRNA vaccines for covid-19 immunization influence further progress with the use of mRNA tumor vaccines. 2. In the References section, listing of the reference #32 is incomplete.